Autism is a neurodevelopmental disorder characterized by specific activity patterns and aberrant social interaction and communication.^[@bib1]^ Genetic and environmental factors have been proposed to account for apparently increasing rates of autism diagnostics.^[@bib2],\ [@bib3]^ Its neurobiological basis is, however, poorly understood and the behavioral phenotypes display a high grade of heterogeneity, leading to the definition of 'autism spectrum disorders\' (ASDs). It has been reported that clinical onset of ASD seems to be preceded by a phase of brain overgrowth in the first years of life followed by decreased growth rates between 5 and 12 years of age, when compared with controls.^[@bib4]^ These abnormalities are paralleled by higher levels of brain-derived neurotrophic factor, insulin growth factors 1 and 2 (IGF-1 and IGF-2), IGF-binding protein 3, growth hormone-binding protein, neurotrophin-4, and a neuroinflammatory response in the ASD brains.^[@bib5],\ [@bib6],\ [@bib7],\ [@bib8]^ Changes in trophic support may account for abnormal brain growth and an altered connectome, thus defining multiple ASD symptoms. Recent pieces of evidence also indicate the role for deregulated processing of the Alzheimer\'s disease (AD)-associated amyloid-*β* (A*β*) precursor protein (APP) in ASD-associated pathology. A*β* is considered to be central for the pathophysiology of AD, which in its genetic and sporadic forms appears to be the most common cause of age-associated dementia. AD is characterized by specific pathological hallmarks represented by extracellular deposits of fibrillar A*β*, intraneuronal accumulation of neurofibrillary tangles due to hyperphosphorylation of cytoskeletal Tau filaments, as well as impairment of neurogenesis. The end result is massive neuronal death and consequent decline in cognitive functions.^[@bib9],\ [@bib10],\ [@bib11]^ In ASD, the AD-associated APP, in particular its neuroprotective processing product or secreted APP*α* (sAPP*α*), was found to be elevated.^[@bib12]^ Current research indicates that abnormalities of the cerebellum, now believed to have a role in cognitive function, are associated with autism; being one of the brain regions where cellular and growth abnormalities are most pronounced in the disorder.^[@bib13],\ [@bib14],\ [@bib15]^

Here we address the question of whether changes of expression in the same set of genes observed in AD neuropathology could also be found in autism; and if this is the case, whether drugs tested not only in the context of autism but also in AD may be considered for therapeutics in these patients. Our study shows altered expression of genes belonging to NOTCH, WNT, AD, and apoptosis pathways in cerebellar samples from autistic individuals. In addition, systems pharmacology analyses of such a pathway that integrates NOTCH, WNT, AD, and apoptosis-related genes suggest magnesium (Mg^2+^) and rapamycin for further therapeutic exploration in the context of autism; two compounds/drugs that therapeutic use have already been discussed for different AD models.^[@bib16],\ [@bib17]^

Results
=======

Subnetwork analyses of AD-related pathways reveal transcriptional changes in the cerebellum of autistic individuals
-------------------------------------------------------------------------------------------------------------------

For analyzing the potential transcriptional changes in genes belonging to pathways typically associated to AD pathology in autism, we constructed four subnetworks models of NOTCH ([Supplementary Figure S1A](#sup1){ref-type="supplementary-material"}), WNT ([Supplementary Figure S2A](#sup1){ref-type="supplementary-material"}), AD ([Figure 1a](#fig1){ref-type="fig"}), and apoptosis ([Supplementary Figure S3A](#sup1){ref-type="supplementary-material"}) pathways. These subnetworks contained 41, 136, 171, and 70 respective genes/proteins ([Supplementary Tables S1--S4](#sup1){ref-type="supplementary-material"}). Next, we performed a focused microarray analysis of the genes belonging to each subnetwork by using samples from the cerebellum of autistic patients *versus* controls. In 31% (116 out of 374) of the genes belonging to these *in silico* models were differentially expressed in ASD samples (corrected *P*-value \<0.05) ([Table 1](#tbl1){ref-type="table"}). More specifically, ∼30% for NOTCH (12 genes), ∼23% for WNT (31 genes), \>40% for AD (69 genes), and ∼26% for apoptosis (18 genes). *UQCRC1*, *NDUFS3*, *NDUFA9*, *JUN*, *CIDEB*, *CDC42*, *NDUFA6*, *NDUFB7*, *NDUFA1*, and *COX4I1* ([Table 1](#tbl1){ref-type="table"}) were the top 10 genes that displayed most significant changes in their expression. The downregulated genes were cytochrome *c* reductase and NADH dehydrogenase related. Among the AD-related genes, upregulation of *GRIN1*, the channel-forming subunit of NMDA glutamate receptors, and *MAP3K1*, known activator of JNK and ERK pathways with anti-apoptotic effect, were also found together with significantly lower expression of presinilin 2 (*PSEN2*) and *APBB1* ([Table 1](#tbl1){ref-type="table"}).

The *in silico* models were subsequently subjected to further analysis with the ViaComplex software that plots the expression mean values derived from each diseased sample (autism) over the expression of healthy control samples (*z* axis) in the network model (NOTCH, WNT, AD, and apoptosis), presenting them as two-dimensional (2D) ViaComplex-generated landscapes ([Supplementary Figures S1B--S3B](#sup1){ref-type="supplementary-material"}; and [Figure 1b](#fig1){ref-type="fig"}). The generated plot visualizes the general landscape of gene expression of diseased samples (autism) *versus* healthy controls for each subnetwork. Expression levels are color coded with warm colors (yellow to red) being indicative of increased expression, whereas cold (green to blue) colors indicate decreased gene expression when compared with control samples. The 2D ViaComplex plots revealed a general upregulation of NOTCH pathway ([Supplementary Figure S1B](#sup1){ref-type="supplementary-material"}) and specific decrease in the expression of mitochondria-related genes (network cluster on the upper left; [Figure 1b](#fig1){ref-type="fig"}).

NOWADA is an integrative network model for NOTCH, WNT, AD, and apoptosis subnetworks
------------------------------------------------------------------------------------

As results presented above showed significant changes in expression of genes belonging to NOTCH, WNT, AD, and apoptosis pathways in cerebellar brain biopsies from ASD patients, our next aim was to test the feasibility of an *in silico* model that is able to integrate these four subnetworks into one single network and therefore to characterize the relevant molecular route. The Venn diagram, which visualizes the level of subnetwork information integration ([Figure 2](#fig2){ref-type="fig"}), shows that the four subnetworks contain common nodes (genes/proteins) allowing communication with one another. Then, by using STRING 9.05 ('Experiments\' and 'Databases\' confidence score of 0.600) and plotting with Cytoscape software, we developed a **NO**TCH-**W**NT-**A**lzheimer\'s **D**isease-Apoptosis (NOWADA) gene/protein interaction network model able to characterize *in silico* these molecular interactions ([Figure 3](#fig3){ref-type="fig"}). The model is composed of 374 genes/proteins interconnecting through 3665 interactions, with only five nodes (*PPP3CA*, *PPP3CB*, *PPP3CC*, *PPP3R1*, and *PSEN1*) contributing to maximum three groups (NOTCH, WNT, AD, or apoptosis subnetworks) at the same time.

Identification of hey hub genes/proteins within NOWADA network in the context of autism
---------------------------------------------------------------------------------------

In order to describe the global characteristics of the network, we measured centralities^[@bib18]^ or topological network properties as follows: (i) 'stress\', representing how much a node (gene/protein) is traversed by a high number of ideal routes or short paths in a network. Then, a gene/protein traversed by higher number of short paths will be, by definition, more stressed. (ii) 'connectivity or degree\' that quantifies the local topology of each node by summing up the number of its adjacent nodes. (iii) 'Betweenness\', which is similar to stress as a topological network property, provides a more informative and elaborated centrality index as it measures how frequently the shortest path, connecting every pair of nodes, is going through a third given node. In other words, both 'stress\' and 'betweenness\' give information about the influence of a node over the spread of information throughout the network. (iv) Finally 'closeness\', defined by the inverse of the average length of the shortest paths to access all other proteins in the network, gives an idea about the level of proximity of a node to other nodes or how long it will take the information to spread from a given node to other nodes in the network. Logically, the larger the value, the faster the information spreads. Our focus in this part of the study is to target vulnerable (central) components in NOWADA network with 31% of its genes displaying significant changes in expression in the cerebellum of autistic patients (corrected *P*-values \<0.05). Upon calculation of each centrality value for each gene/protein ([Supplementary Table S5](#sup1){ref-type="supplementary-material"}), we identified the hub-bottlenecks (HBs) of the network that also displayed higher values of 'stress\' and closeness centralities. These network nodes were (in alphabetical order) *APP*, *CALM1*, *CASP3*, *CTNNB1*, *DVL2*, *DVL3*, *EP300*, *FZD5*, *GSK3B*, *MYC*, *NOTCH1*, *PLCB2*, *PRKCA*, and *TP53* ([Supplementary Table S6](#sup1){ref-type="supplementary-material"} and [Figure 4](#fig4){ref-type="fig"}). As central members, these genes/proteins will control the flow of biological information within the network and its disruption (e.g., by drug interaction) could destroy the entire network into small components. Remarkably, *CTNNB1*, gene encoding for *β*-catenin protein ([Supplementary Table S2](#sup1){ref-type="supplementary-material"}), was the node with top values for all the measured centralities ([Supplementary Table S6](#sup1){ref-type="supplementary-material"} and [Figure 4](#fig4){ref-type="fig"}).

Systems pharmacology analysis of NOWADA network suggests Mg^2+^ and rapamycin as most efficient drugs to target the model *in silico*
-------------------------------------------------------------------------------------------------------------------------------------

Previous analysis allowed us to identify central nodes (bottlenecks) with high topological network values. At this stage, as NOWADA network can be considered as a common pathway model for AD and autism, these 14 nodes (genes/proteins) could represent potential targets for both pathologies *in silico*. With the aim of elucidating the most suitable and efficient drugs targeting the network in the context of autism, differential gene expression values were taken into account. Our selection criteria was then as follows: (i) to select drugs targeting higher number of genes/proteins within the network; (ii) from those, to choose the drugs affecting/associated to higher numbers of bottlenecks (preferably, HBs with high values of 'stress\' and 'closeness\' centralities); and (iii) to select drugs that targets, within the network (NOWADA), include higher number of genes with significant changes in expression. Upon systematic review of the literature (see Materials and Methods section), 47 used/proposed drugs for autism therapy were divided in 15 groups and tested for potential interaction/s with genes/proteins of the network model. The groups are acetylcholinesterase inhibitors, allosteric modulators of metabotropic glutamate receptors, antidepressants (SSRI and tricyclic), antiepileptics/anticonvulsants, antiopioids, antipsychotics, complementary and alternative medicines, inhibitors of mTOR, neurohormones, NMDAR (agonists and antagonists), mood stabilizers, psycoestimulants, and sympatholytic medications. Incidentally, 36 out of the 47 autism-related drugs have already been studied in different models of AD (in humans or *in vivo*) for potential therapeutic use^[@bib19],\ [@bib20],\ [@bib21],\ [@bib22]^ ([Supplementary Table S7](#sup1){ref-type="supplementary-material"}). Upon using STITCH 3.1, we confirmed that 16 out of the 47 tested drugs had positive hits with at least one gene/protein of NOWADA network (with 'Experiments\' and 'Databases\' as input options; confidence score of 0.600). These therapeutic agents were (in alphabetical order) as follows: chlorpromazine, clozapine, D-cycloserine, fluoxetine, galantamine, haloperidol, imipramine, lithium, luteolin, Mg^2+^, melatonin, memantine, olanzapine, rapamycin, valproic acid, and ziprasidone. Most targeted nodes were *GSK3B* (glycogen synthase kinase 3*β,* 6 hits), *AKT1* (5 hits), *CALM1* (3 hits), *GRIN1* (3 hits), *GRIN2B* (3 hits), *CHRNA7* (2 hits), *GRIN2A* (2 hits), and *JUN* (2 hits) ([Supplementary Table S9](#sup1){ref-type="supplementary-material"}). Except for *CHRNA7*, our systematic review of the literature could confirm the expression of the indicated gene products in neuronal and/or glial cells (astroglia, microglia, and oligodendroglia; [Supplementary Table S9](#sup1){ref-type="supplementary-material"}), thus representing both neuronal and glial targets. When looking into the characteristics of the tested compounds/drugs--genes/protein interactions, Mg^2+^ and rapamycin are highlighted as the most efficient drugs *in silico* to target this disrupted pathway, which is here represented *in silico* by NOWADA network ([Supplementary Table S10](#sup1){ref-type="supplementary-material"}). More specifically, Mg^2+^ interacts with 32 genes/proteins; among those, eight differentially expressed genes in the cerebellum of autistic patients: the upregulated *EIF2AK2* (corrected *P*-value=0.002850857) and *CAMK2D* (corrected *P*-value=0.034576294), as well as the downregulated *CDC42* (corrected *P*-value=0.002000135), *COX5A* (corrected *P*-value=0.003530677), *NDUFV1* (corrected *P*-value=0.011017543), *NDUFS8* (corrected *P*-value=0.014197263), *RAC3* (corrected *P*-value=0.014704894), and *CALM2* (corrected *P*-value=0.032263251) ([Figure 5](#fig5){ref-type="fig"}). In order to elucidate the biological processes that Mg^2+^ could be influencing in this context, a functional enrichment analysis of the genes belonging to the Mg^2+^ subnetwork was performed. The top 10 affected processes are as follows: phosphorylation, phosphorus metabolic process or phosphate-containing compound metabolic process, neuromuscular process, regulation of neurological system process, protein amino-acid autophosphorylation, small GTPase-mediated signal transduction, mitochondrial electron transport (NADH to ubiquinone), positive regulation of cell projection organization, and intracellular signaling cascade (corrected *P-*value \<0.05; [Supplementary Table S11](#sup1){ref-type="supplementary-material"}).

Discussion
==========

Here we studied the possible neurobiological mechanism involved in the excessive rates of early brain overgrowth observed in autism^[@bib4]^ based on the recent evidence, indicating a possible role for the AD-associated APP processing pathway in ASD.^[@bib23]^ Proliferation in the brain results from balancing proliferative rates and developmental apoptosis (i.e., more proliferation and less death will result in a larger brain).^[@bib24]^ APP is proteolytically processed by two competing pathways such as the amyloidogenic (*β*-secretase-mediated) and the non-amyloidogenic (*α*-secretase-mediated) pathways.^[@bib25]^ sAPP*β* (secreted APP*β*) and the neurotoxic A*β* peptide are generated from APP and released to the extracellular site by proteolytic cleavage of both *β*- and *γ*-secretases.^[@bib26]^ A*β* has been suggested to have a critical role in neurotoxicity and apoptotic events seen in AD.^[@bib27]^ In contrast, the non-amyloidogenic product sAPP*α* and the p3 peptide are formed by proteolytic cleavage of both *α*- and *γ*-secretases^[@bib26]^ sAPP*α* exerts proliferative effects on neural progenitor cells isolated from embryonic brains and is able to enhance synaptogenesis, neurite outgrowth, cell survival, and cell adhesion;^[@bib28],\ [@bib29],\ [@bib30],\ [@bib31]^ and APP seems to be able to modulate the neuronal precursors migration.^[@bib32]^ As *γ*-secretase cleaves several proteins that include APP and Notch,^[@bib33]^ the potential role of NOTCH signaling pathway in the genesis of AD is also considered.^[@bib34]^ Focused microarray analysis used in this study demonstrated that expression of 40% of the AD-related genes was altered in the cerebellum of autistic patients (corrected *P*-value \<0.05), these changes mainly represented by downregulation of NADH dehydrogenases and cytochrome *c* oxidases ([Table 1](#tbl1){ref-type="table"}). These results reflect deficient mitochondrial respiratory chain that is consistent with recent reports describing mitochondrial dysfunction in ASD;^[@bib35]^ or may indirectly confirm tight Notch--mitochondria interconnections.^[@bib36]^ An upregulation of *GRIN1* (corrected *P*-value=0.03916101), the channel-forming subunit NR1 of NMDA glutamate receptors and *MAP3K1* (corrected *P*-value=0.038406592), also known as *MEKK1* or *MAPK/ERK Kinase Kinase 1*, which activates JNK and ERK pathways with anti-apoptotic effect,^[@bib37]^ were also found among the AD-related genes in ASD samples ([Table 1](#tbl1){ref-type="table"}). *In vivo* studies have shown that stressful events during gestation can increase the expression of NMDA receptors in the brain.^[@bib38]^ The altered expression of NMDA receptors may be related to epigenetic regulation (e.g., DNA hypomethylation) because histone lysine methylation at gene promoters is involved in developmental regulation and maintenance of region-specific expression patterns of ionotropic and metabotropic glutamate receptors in the brain.^[@bib39]^ Furthermore, glutamate receptors expression and/or their activity can modulate the APP processing mechanisms.^[@bib40]^ High glutamate receptors activation and consequent increase in intracellular calcium activate the ERK signaling cascade, enhancing *α*-secretase cleavage of APP, and thus reducing APP processing into A*β*. An increase in *α*-secretase activity may lead to higher production of sAPP*α*.^[@bib26]^ In this study, we hypothesize that deregulated glutamatergic synaptic transmission/plasticity, caused by increased expression of *GRIN1* and hence increased density of NMDA receptors, may affect neuronal growth in autism by shifting APP processing to the production of sAPP*α* through ERK-mediated *α*-secretase activity. SAPP*α*, in turn, may facilitate proliferation by activating the PI3K/Akt/mTOR pathway.^[@bib41],\ [@bib42]^ Based on the present data and existing literature, we proposed this model ([Figure 6](#fig6){ref-type="fig"}) as a mechanism that could explain the focal modification of neurogenesis, migration, and alterations of the cytoarchitecture of brain cortex, subcortical structures and cerebellum observed in individuals with autism.^[@bib43]^ Consequently, the decrease in expression of mitochondrial enzymes observed in our array ([Table 1](#tbl1){ref-type="table"}) may represent a compensatory mechanism to contain Ca^2+^ overload-induced apoptosis in these cells. It has already been reported that compromised mitochondria accumulate (observed by increased mitochondrial mass) in pyramidal neurons in temporal cortex of younger ASD subjects.^[@bib44]^ Moreover, PSEN1 and PSEN2 are believed to have almost overlapping cellular functions and contribute to diverse physiological processes, such as regulation of Ca^2+^ homeostasis, protein transport and turnover, autophagy, cell adhesion, neurotransmitter release, and axon guidance.^[@bib45]^ PSEN2, however, seems to be responsible for endoplasmic reticulum (ER) and mitochondria interactions.^[@bib46]^ Closer ER--mitochondria juxtaposition (regulated by PSEN2) may expose mitochondria to excessive Ca^2+^ stimulation, triggering the apoptotic cascade by mitochondria Ca^2+^ overload. In our array analysis, we found that *PSEN2* is downregulated (corrected *P*-value=0.005968353) in the cerebellum of autistic patients ([Table 1](#tbl1){ref-type="table"}), which could represent another compensatory mechanism to reduce Ca^2+^ overload-induced apoptosis. Our hypothesis is further supported by the following observations: (i) mutant mice in which glutamate receptors are overstimulated by knocking out (KO) glutamate transporters GLAST and GLT1, and thus leading to excessive glutamatergic signaling in the prenatal stage, compromising early brain development via overstimulation of NMDARs. NR1 deletion in double KO mice almost completely rescued multiple brain defects including cortical, hippocampal, and olfactory bulb disorganization and defective corticothalamic and thalamocortical axonal projections;^[@bib47]^ (ii) opposite to what it is seen in AD patients, higher levels of sAPP*α* have been described in plasma from autistic children when compared with controls, favoring an increased *α*-secretase pathway;^[@bib12],\ [@bib48]^ (iii) evidence of autoimmunity and persistent systemic immune activation have been reported in ASD,^[@bib49]^ and mice overexpressing human sAPP*α* indeed exhibit higher T-cell cytokine secretion together with reduced CD4^+^ and higher CD8^+^ T-cell populations in splenocytes when compared with wild-type animals. These animals also display hypoactivity, impaired social interaction, elevated levels of brain glial fibrillary acidic protein (GFAP) expression, and altered Notch1 and interleukin-6 levels.^[@bib50]^ In the brain of autistic individuals, increased expression of GFAP in the areas with disturbed neuronal architecture has been detected together with interleukin-6, interleukin-8, tumor necrosis factor-*α*, interferon-*γ*, and granulocyte--macrophage colony-stimulating factor, suggesting astrogliotic response and potential alterations in neurogenesis and neuronal migration.^[@bib51],\ [@bib52],\ [@bib53],\ [@bib54]^ (iv) Finally, we observed a significant decrease (corrected *P*-value=0.024237411) in expression of *APBB1* (A*β* A4 precursor protein binding, family B, member 1; or *F65*) ([Table 1](#tbl1){ref-type="table"}). *In vitro* F65 overexpression induces a marked increase in A*β* secretion, whereas A*β* secretion is decreased in Fe65 knockdown cells and also in hippocampal neurons of Fe65/Fe65L1 KO mice.^[@bib55],\ [@bib56],\ [@bib57]^

Systems pharmacology analyses of NOWADA network revealed that Mg^2+^ and rapamycin could efficiently target this pathway *in silico*, when compared to other drugs ([Supplementary Table S10](#sup1){ref-type="supplementary-material"}). RhoGAPs, regulatory molecules of RHO GTPases (e.g., *CDC42*, *RHOA*, and *RAC1*), which altered expression were shown in autism,^[@bib3]^ use Mg^2+^ as a cofactor to reach catalytic efficiency and specificity in GTP hydrolysis ([Supplementary Table S11](#sup1){ref-type="supplementary-material"}).^[@bib58]^ Furthermore, *GSK3B*, a HB in our network model ([Supplementary Table S6](#sup1){ref-type="supplementary-material"}), is a ubiquitous serine/threonine kinase that catalyzes the transfer of *γ*-phosphate of ATP to the hydroxyl oxygen of the Ser and Thr residues of a kinase-specific protein substrate is a Mg^2+^-dependent kinase.^[@bib59]^ Its aberrant function has been linked to diverse neurological disorders such as AD.^[@bib60]^ Lower concentrations of Mg^2+^ were described in children with autism.^[@bib61]^ Similarly, in AD patients, Mg^2+^ concentrations in the brain seem to be significantly lower when compared with age-matched normal individuals.^[@bib62]^ Recently, it was suggested that elevation of brain Mg^2+^ concentration in the brain exerts substantial synaptoprotective effects in an *in vivo* model of AD, and hence Mg^2+^ may have therapeutic potential for treating AD in humans.^[@bib17]^ In autism, positive behavioral effects of combined Mg^2+^ and pyridoxine treatment were described;^[@bib63]^ combination that was also proposed to be beneficial in ASD patients that experience seizures.^[@bib64]^ The therapeutic usage of rapamycin (mTOR inhibitor) in ASD is nowadays discussed. TSC1 and TSC2 are upstream inhibitory regulators of mTOR activity, and studies performed in TSC2^+/−^ mice showed that treatment with rapamycin can rescue synaptic plasticity and reverse the abnormal late phase of long-term potentiation.^[@bib20]^ These results encourage future clinical trials with TOR inhibitors as pharmacological treatment of ASD.

We believe that the computational analyses performed in this study gave valuable clues to (i) develop a model that may explain the aberrant brain overgrowth and impaired neuronal connectivity observed in these children; and (ii) refer to the need of further therapeutic exploration of Mg^2+^- and rapamycin-based treatments in animal models and clinical trials with autistic patients.

Materials and Methods
=====================

Development of gene/protein network models
------------------------------------------

NOTCH, WNT, AD, and apoptosis subnetwork models were developed through (i) extracting the information provided by the KEGG PATHWAY database (<http://www.genome.jp/kegg/pathway.html>; NOTCH pathway: map04330, WNT pathway: map 04310; AD pathway: map05010, and apoptosis pathway: map04210); and (ii) by establishing the interactions between genes/proteins with the database resource Search Tool for the Retrieval of Interacting Genes/Proteins STRING version 9.05 (<http://string-db.org/>); with 'Experiments\' and 'Databases\' as input options and a confidence score of 0.600. STRING is a well-known public database with information about direct and indirect functional protein--protein interactions. The genes/proteins belonging to NOTCH, WNT, AD, and apoptosis subnetwork models were identified by the HUGO Gene Symbol^[@bib65]^ and Ensemble protein ID ([Supplementary Tables S1--S4](#sup1){ref-type="supplementary-material"}). Once they were selected, the links between two different nodes (genes/proteins), provided by the STRING database, are saved in data files to be processed in the Medusa interface^[@bib66]^ and visualized as a subnetwork (NOTCH, WNT, AD, or apoptosis). The Venn diagram was constructed by using the freely available software system R (<http://www.r-project.org>)^[@bib67]^ in order to visualize the grade of molecular relation (common genes/proteins) between the generated subnetworks. The *in silico* network model integrating NOTCH, WNT, AD, and apoptosis subnetworks (NOWADA) was developed by using again STRING version 9.05 with 'Experiments\' and 'Databases\' as input options and a confidence score of 0.600 (0.400 is considered 'medium confidence\') and plotted by using Cytoscape, an open source platform for complex network analysis and visualization (<http://www.cytoscape.org/>).^[@bib68]^

Data acquisition and processing, determination of variably expressed genes, statistics, and gene expression network visualization
---------------------------------------------------------------------------------------------------------------------------------

Microarray data (raw data;.cel files) were obtained from the Geo DataSets database (<http://www.ncbi.nlm.nih.gov/geo/>). The data set (GSE38322), originally contributed by Ginsberg *et al.*,^[@bib69]^ is publicly available; it contains data from cerebellar brain tissue of autistic patients and control subjects. Experimental assays are described in full in the original publication and details include the selection criteria of patients (both inclusion and exclusion criteria) and diagnostic profile.^[@bib69]^ For elucidating the differential expression of members from the NOTCH, WNT, AD, and apoptosis subnetworks, expression data were filtered from probes with \<0.05 signal detection *P-*values and normalized by using the lumi package from R and robust spline normalization. For differential gene expression analysis, normalized data of cerebellar samples from patients *versus* controls were analyzed by using the limma package from R^[@bib67]^ and false discovery rate (FDR) control for statistical assessment of the microarray data (corrected *P*-values \<0.05 were considered significant). Specific corrected *P*-values for each differentially expressed gene are provided ([Table 1](#tbl1){ref-type="table"}). In order to visualize the general landscape of gene expression *in silico*, gene expression in samples from autism were plotted *versus* the expression found in healthy controls to be visualized with the ViaComplex software, a tool that was previously developed and validated in our laboratory.^[@bib70]^ This software plots gene expression over the Medusa network (in a color scale) by overlapping functional input data (microarray expression data) with interaction information (NOTCH, WNT, AD, and apoptosis subnetworks) and distributes the microarray signal according to the coordinates of the nodes and its interactions in the network of interest.

Elucidation of network centralities to predict the relevance of genes in the overall network architecture
---------------------------------------------------------------------------------------------------------

Topological network properties of the genes/proteins integrating the network (NOWADA) were calculated by using Cytoscape.^[@bib68]^ Numeric values corresponding to the properties of each node are additionally provided ([Supplementary Table S5](#sup1){ref-type="supplementary-material"}). Thresholds for selection criteria of the most relevant nodes according to their centrality values were established considering one s.d. of the mean for each topological network properties: 'stress\': 48 919.44 (mean=15251.9); 'connectivity or degree\': 35.84815 (mean=19.59893); 'betweenness\': 0.022270086 (mean=0.005765439); and 'closeness\': 0.372488254 (mean=0.325097663). Centrality values were plotted in graphs by using OriginLab (<http://www.originlab.com/index.aspx?go=Products/OriginPro>). Nodes (genes/proteins) with high connectivity (above the threshold) and low betweenness centrality (below the threshold) are considered hub-non-bottlenecks and those ones with a value above the thresholds for both connectivity and betweenness centrality are referred to as HBs. Similarly, non-HBs (NH-Bs) are nodes with low connectivity and high betweenness centrality, and non-hub-non-bottlenecks are nodes with both connectivity and betweenness centrality values below the thresholds.^[@bib18]^

*In silico* development of compound (drug)-gene/protein network model
---------------------------------------------------------------------

To construct the compound (drug)-gene/protein network models, we first performed a systematic review of relevant literature associated with autism or AD therapy in the PubMed database (<http://www.ncbi.nlm.nih.gov/pubmed/>). These articles were obtained by using the two terms 'autism\' and 'ASD\' and combining them with the following terms: 'Alzheimer\'s disease\', 'therapy\', 'therapeutics\', 'treatment\', and/or 'drug\', respectively. Moreover, compound identifier, formula, description, and selected autism- and AD-related reports (with PMID) for these drugs ([Supplementary Table S6](#sup1){ref-type="supplementary-material"}) are additionally provided with KEGG DRUG (<http://www.genome.jp/kegg/drug/>), the Search Tool for Interactions of Chemicals STITCH version 3.1 (<http://stitch.embl.de/>), and PubMed database as sources of information. Second, these drugs were submitted to *in silico* analysis by searching the number of genes/proteins within NOWADA network that are targeted by the selected drugs. To achieve this goal, STITCH version 3.1 (<http://stitch.embl.de/>) was used with 'Experiments\' and 'Databases\' as input options and a confidence score of 0.600 (0.400 is considered 'medium confidence\'). A list with the most drug-targeted network nodes (genes/proteins) is also provided ([Supplementary Table S8](#sup1){ref-type="supplementary-material"}). Again, the links between two different nodes (drug-genes/proteins), provided by the STITCH database, is saved in data files to be handled in the Medusa interface and visualized as a subnetwork. For screening potential cellular targets of the most drug-targeted network nodes (NOWADA), another systematic review of both original research articles and reviews was performed in PubMed database. These articles were obtained by using the genes/proteins name or symbol and combining them with the following terms: 'Neuronal\', 'Neuron\', 'Astroglia\', 'Astrocyte\', 'Microglia\', 'Oligodendroglia\', and/or 'Oligodendrocyte\' ([Supplementary Table S9](#sup1){ref-type="supplementary-material"}).The selected references confirm the expression of the indicated gene products in brain cells. Note that the selected references do not cover therapeutic modalities, age or brain region specificity.

Functional enrichment analysis (biological processes)
-----------------------------------------------------

The biological processes of the genes products belonging to the subnetwork model of interactions was determined by using the database for annotation, visualization, and integrated discovery DAVID v6.7 (<http://david.abcc.ncifcrf.gov/>), giving a number of functional annotation tools to researchers for better comprehension of the biological meaning behind any large list of genes. Only those biological processes with corrected *P-*value \<0.05 (FDR) were selected. Specific corrected *P*-values for each biological process are provided ([Supplementary Table S9](#sup1){ref-type="supplementary-material"}).

A graphical abstract, summarizing the contents and the methodological approaches used for the present study, is also provided ([Figure 7](#fig7){ref-type="fig"}).
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![AD subnetwork analysis. (**a**) General landscape of interactions between genes/proteins belonging to the AD pathway (map05010; KEGG Pathway; <http://www.genome.jp/kegg/pathway.html>). The *in silico* network model was developed by using the STRING 9.05 database resource search tool, under a confidence score of 0.600 and using 'Databases\' and 'Experiments\' as input options. (**b**) Focused microarray analyses of AD-related genes in the cerebellum of autistic patients *versus* healthy controls over the *in silico* model. The *z* axis for representing the relative gene expression was constructed by using the ViaComplex software](cddis2014227f1){#fig1}

![Venn diagram showing information integration from the studied subnetworks. NOTCH, WNT, AD, and apoptosis models contain common nodes (genes/proteins) with, at least, one subnetwork](cddis2014227f2){#fig2}

![Network model of interactions between genes/protein belonging to NOTCH, WNT, AD, and apoptosis subnetworks (NOWADA network). The present model was developed by using the STRING 9.05 database resource search tool, under a confidence score of 0.600, and by using 'Databases\' and 'Experiments\' as input options and visualized by plotting it with Cytoscape software. The number of subnetwork contributions of each gene/protein within the network is represented in the figure as indicated in the inset](cddis2014227f3){#fig3}

![Analysis of the topological properties (**a**--**c**) of genes/proteins belonging to the network (NOWADA). Dashed lines are indicating the threshold value for each property. Upregulated and downregulated genes in the subnetwork are marked with red and blue triangles, respectively, as indicated in the inset. Note that NH-Bs and HBs distinguish non-HBs from HBs, respectively](cddis2014227f4){#fig4}

![Mg^2+^ subnetwork analysis. (**a**) *In silico* network model of the interactions between Mg^2+^ and genes/proteins belonging to the network (NOWADA), developed by using STITCH 3.1 with 'Experiments\' and 'Databases\' as input options and a confidence score of 0.600. (**b**) Actions view representation between the network nodes by 'catalysis\' (yellow). (**c**) Actions view representation between the network nodes by 'binding\' (white color). (**d**) Actions view representation between the network nodes by 'inhibition\' (red color). Upregulated and downregulated genes in the subnetwork are marked with red and blue triangles, respectively, as indicated in the inset](cddis2014227f5){#fig5}

![Hypothetical model of the synaptic mechanism regulating A*β* production and the link to aberrant brain growth and connectivity in autism. The development of living organisms parallels to a so-called physiological 'intrinsic developmental stress\', which is associated to massive internal changes during morphogenesis, and thus contributes to the time window of vulnerability to the environment. Development and severity of ASD are likely to arise from complex interactions between pre-existing genetic vulnerability/ies in these children, the exposure to noxious environmental factors, and the timing of the stressful event(s); given that prenatal life, infancy, childhood, and adolescence are critical periods characterized by increased vulnerability to stressors.^[@bib2],\ [@bib3]^ Glial activation and neuroinflammation seem to persist during adulthood in autism, and early brain overgrowth in autism could be a consequence of an over-activation of neural proliferation in a trial to compensate the cellular loss induced by environmental stress/ors, triggering precipitous/uncontrolled migration and misdistribution of neurons among different brain areas. Our model proposed that aberrant epigenetic regulation may lead to increased density of NMDA receptors and, therefore, to increased Ca^+2^ entry and stimulation of ERK-dependent *α*-secretase activity. The decrease in mitochondrial enzymatic activity together with the downregulation of PSEN2 at the ER may represent a compensatory mechanism to reduce the Ca^2+^ overload-induced apoptosis. PSEN2 downregulation may diminish the interaction between ER and mitochondria, reducing its Ca^+2^ uptake. In turn, mitochondrial mass would increase most likely to maintain the cellular ATP levels. Higher levels of sAPP*α* would activate the PI3K/Akt/mTOR pathway resulting in proliferation, aberrant brain growth, and disruption of synaptic plasticity and connectome](cddis2014227f6){#fig6}

![Abstract workflow summarizing the different approaches used for the present study. The information from the different pathways (NOTCH, WNT, AD, and apoptosis) was gathered from KEGG pathway (<http://www.genome.jp/kegg/pathway.html>) to develop the subnetworks. The differential expression of the genes belonging to each subnetwork was analyzed in the cerebellum of autistic patients by using R. A Venn diagram showed common genes/proteins between NOTCH, WNT, AD, and apoptosis pathways. Thereafter, a network model was developed for integrating these subnetworks into one single gene/protein interaction network model (NOWADA network) by using STRING 9.05 and Cytoscape tools. Further elucidation of the topological network properties revealed a number of potential molecular targets or 'vulnerable\' points of the *in silico* model and therapeutic agents used in autism targeting central nodes of the network were studied (STITCH 3.1). Finally, a subnetwork representing the interaction between Mg^2+^ and genes/proteins from NOWADA network was constructed and a functional enrichment analysis was performed (DAVID v6.7) to elucidate the biological processes potentially affected by this compound](cddis2014227f7){#fig7}

###### Differentially expressed genes from the NOTCH, WNT, Alzheimer\'s disease, and apoptosis subnetworks in the cerebellum of autistic patients

  **Gene symbol**   **Alias and/or description**                                                               **Ensembl ID (ENSP)**   **Differential gene expression** (**Up/down)**  **Corrected** ***P-*****value (FDR)**    **Subnetwork contribution/s**
  ----------------- ----------------------------------------------------------------------------------------- ----------------------- ------------------------------------------------ --------------------------------------- -------------------------------
  *UQCRC1*          Ubiquinol--cytochrome *c* reductase core protein I                                            ENSP00000203407                           Down                       0.001062657                                           AD
  *NDUFS3*          NADH dehydrogenase (ubiquinone) Fe-S protein 3, 30 kDa (NADH-coenzyme Q reductase)            ENSP00000263774                           Down                       0.001722868                                           AD
  *NDUFA9*          NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 9, 39 kDa                                 ENSP00000266544                           Down                       0.00179604                                            AD
  *JUN*             Jun oncogene                                                                                  ENSP00000360266                            Up                        0.001921098                                           WNT
  *CIDEB*           Cell death-inducing DFFA-like effector b                                                      ENSP00000258807                           Down                       0.001949191                                           APO
  *CDC42*           Cell division cycle 42 (GTP-binding protein, 25 kDa)                                          ENSP00000314458                           Down                       0.002000135                                           WNT
  *NDUFA6*          NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 6, 14 kDa                                 ENSP00000330937                           Down                       0.002033295                                           AD
  *NDUFB7*          NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 7, 18 kDa                                  ENSP00000215565                           Down                       0.002205663                                           AD
  *NDUFA1*          NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 1, 7.5 kDa                                ENSP00000360492                           Down                       0.002205663                                           AD
  *COX4I1*          Cytochrome *c* oxidase subunit IV isoform 1                                                   ENSP00000253452                           Down                       0.002246413                                           AD
  *NCSTN*           Nicastrin                                                                                     ENSP00000294785                            Up                        0.002354256                                         AD NOT
  *UQCRC2*          Ubiquinol--cytochrome *c* reductase core protein II                                           ENSP00000268379                           Down                       0.002354256                                           AD
  *NDUFS4*          NADH dehydrogenase (ubiquinone) Fe-S protein 4, 18 kDa (NADH-coenzyme Q reductase)            ENSP00000296684                           Down                       0.002459308                                           AD
  *CYC1*            Cytochrome *c*-1                                                                              ENSP00000317159                           Down                       0.002656014                                           AD
  *COX8A*           Cytochrome *c* oxidase subunit 8A (ubiquitous)                                                ENSP00000321260                           Down                       0.002656014                                           AD
  *NDUFB4*          NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 4, 15 kDa                                  ENSP00000184266                           Down                       0.002688877                                           AD
  *EIF2AK2*         Eukaryotic translation initiation factor 2-alpha kinase 2                                     ENSP00000233057                            Up                        0.002850857                                           AD
  *BID*             BH3-interacting domain death agonist                                                          ENSP00000318822                           Down                       0.002892499                                         AD APO
  *NDUFA4*          NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4, 9 kDa                                  ENSP00000339720                           Down                       0.003092192                                           AD
  *WNT3*            Wingless-type MMTV integration site family, member 3                                          ENSP00000225512                            Up                        0.003122302                                           WNT
  *NDUFAB1*         NADH dehydrogenase (ubiquinone) 1, alpha/beta subcomplex, 1, 8 kDa                            ENSP00000007516                           Down                       0.003262718                                           AD
  *NDUFA11*         NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 11, 14.7 kDa                              ENSP00000311740                           Down                       0.003262718                                           AD
  *COX5A*           Cytochrome *c* oxidase subunit Va                                                             ENSP00000317780                           Down                       0.003530677                                           AD
  *PRKCA*           Protein kinase C, alpha                                                                       ENSP00000284384                            Up                        0.003532751                                         APO WNT
  *NDUFB9*          NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 9, 22 kDa                                  ENSP00000276689                           Down                       0.003532751                                           AD
  *NDUFA2*          NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 2, 8 kDa                                  ENSP00000252102                           Down                       0.003622328                                           AD
  *COX5B*           Cytochrome *c* oxidase subunit Vb                                                             ENSP00000258424                           Down                       0.003627494                                           AD
  *BCL2*            B-cell CLL/lymphoma 2                                                                         ENSP00000329623                            Up                        0.003686548                                           APO
  *PRICKLE2*        Prickle homolog 2 (*Drosophila*)                                                              ENSP00000295902                            Up                        0.003858642                                           WNT
  *SDHB*            Succinate dehydrogenase complex, subunit B, iron--sulfur (Ip)                                 ENSP00000364649                           Down                       0.003949261                                           AD
  *NDUFA10*         NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 10, 42 kDa                                ENSP00000252711                           Down                       0.004023111                                           AD
  *NDUFB2*          NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 2, 8 kDa                                   ENSP00000247866                           Down                       0.00417954                                            AD
  *NDUFB6*          NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6, 17 kDa                                  ENSP00000369176                           Down                       0.00420016                                            AD
  *NDUFA7*          NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 7, 14.5 kDa                               ENSP00000301457                           Down                       0.004449939                                           AD
  *NDUFB3*          NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 3, 12 kDa                                  ENSP00000237889                           Down                       0.004449939                                           AD
  *UQCRB*           Ubiquinol--cytochrome *c* reductase-binding protein                                           ENSP00000287022                           Down                       0.004918915                                           AD
  *NCOR2*           Nuclear receptor co-repressor 2                                                               ENSP00000348551                            Up                        0.005223194                                           NOT
  *LRP5*            Low density lipoprotein receptor-related protein 5                                            ENSP00000294304                            Up                        0.005717875                                           WNT
  *BAD*             BCL2-associated agonist of cell death                                                         ENSP00000309103                           Down                       0.005763042                                         AD APO
  *UQCRH*           Ubiquinol--cytochrome *c* reductase hinge protein                                             ENSP00000309565                           Down                       0.005906155                                           AD
  *PSEN2*           Presenilin 2 (Alzheimer disease 4)                                                            ENSP00000355747                           Down                       0.005968353                                         AD NOT
  *NDUFA13*         NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 13                                        ENSP00000380364                           Down                       0.00609761                                            AD
  *NDUFB10*         NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 10, 22 kDa                                 ENSP00000268668                           Down                       0.006262982                                           AD
  *COX6C*           Cytochrome *c* oxidase subunit VIc                                                            ENSP00000297564                           Down                       0.006681564                                           AD
  *UQCRQ*           Ubiquinol--cytochrome *c* reductase, complex III subunit VII, 9.5 kDa                         ENSP00000367934                           Down                       0.00745614                                            AD
  *NDUFA3*          NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 3, 9 kDa                                  ENSP00000398290                           Down                       0.007600014                                           AD
  *HEY1*            Hairy/enhancer-of-split related with YRPW motif 1                                             ENSP00000338272                           Down                       0.00784934                                            NOT
  *DAAM1*           Disheveled associated activator of morphogenesis 1                                            ENSP00000247170                            Up                        0.007909188                                           WNT
  *PPP3CC*          Protein phosphatase 3 (formerly 2B), catalytic subunit, gamma isoform                         ENSP00000240139                           Down                       0.008118636                                       AD APO WNT
  *COX7B*           Cytochrome *c* oxidase subunit VIIb                                                           ENSP00000417656                           Down                       0.008265168                                           AD
  *NDUFB11*         NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 11, 17.3 kDa                               ENSP00000276062                           Down                       0.008503556                                           AD
  *NFKB1*           Nuclear factor of kappa light polypeptide gene enhancer in B cells 1                          ENSP00000226574                            Up                        0.008570685                                           APO
  *KAT2B*           K(lysine) acetyltransferase 2B                                                                ENSP00000263754                            Up                        0.009111103                                           NOT
  *NDUFA12*         NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 12                                        ENSP00000330737                           Down                       0.009479959                                           AD
  *UQCRFS1*         Ubiquinol--cytochrome *c* reductase, Rieske iron--sulfur polypeptide 1                        ENSP00000306397                           Down                       0.009524703                                           AD
  *NDUFS5*          NADH dehydrogenase (ubiquinone) Fe-S protein 5, 15 kDa (NADH-coenzyme Q reductase)            ENSP00000362058                           Down                       0.009998423                                           AD
  *BAX*             BCL2-associated X protein                                                                     ENSP00000293288                           Down                       0.010349538                                           APO
  *CYCS*            Cytochrome *c*, somatic                                                                       ENSP00000307786                           Down                       0.010843806                                           AD
  *NDUFV1*          NADH dehydrogenase (ubiquinone) flavoprotein 1, 51 kDa                                        ENSP00000322450                           Down                       0.011017543                                           AD
  *RBX1*            Ring-box 1                                                                                    ENSP00000216225                           Down                       0.01185897                                            WNT
  *NFKBIA*          Nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha           ENSP00000216797                            Up                        0.012804007                                         AD APO
  *AXIN2*           Axin 2                                                                                        ENSP00000302625                            Up                        0.01310984                                            WNT
  *CSNK1G1*         Casein kinase 1, gamma 1                                                                      ENSP00000305777                            Up                        0.013381084                                           WNT
  *NDUFS8*          NADH dehydrogenase (ubiquinone) Fe-S protein 8, 23 kDa (NADH-coenzyme Q reductase)            ENSP00000315774                           Down                       0.014197263                                           AD
  *HSD17B10*        Hydroxysteroid (17-beta) dehydrogenase 10                                                     ENSP00000168216                           Down                       0.014254764                                           AD
  *RAC3*            Ras-related C3 botulinum toxin substrate 3 (rho family, small GTP-binding protein Rac3)       ENSP00000304283                           Down                       0.014704894                                           WNT
  *DTX3*            Deltex homolog 3 (*Drosophila*)                                                               ENSP00000338050                           Down                       0.015144277                                           NOT
  *CDK5*            Cyclin-dependent kinase 5                                                                     ENSP00000297518                           Down                       0.015567567                                           AD
  *CABIN1*          Calcineurin-binding protein 1                                                                 ENSP00000263119                            Up                        0.015953582                                         AD WNT
  *COX7C*           Cytochrome *c* oxidase subunit VIIc                                                           ENSP00000247655                           Down                       0.016686515                                           AD
  *RUVBL1*          RuvB-like 1 (*Escherichia coli*)                                                              ENSP00000318297                           Down                       0.016765972                                           WNT
  *DFFA*            DNA fragmentation factor, 45 kDa, alpha polypeptide                                           ENSP00000366237                            Up                        0.017000844                                           APO
  *NDUFB8*          NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 8, 19 kDa                                  ENSP00000299166                           Down                       0.01782766                                            AD
  *COX6B1*          Cytochrome *c* oxidase subunit VIb polypeptide 1 (ubiquitous)                                 ENSP00000246554                           Down                       0.017845204                                           AD
  *TLE1*            Transducin-like enhancer-of-split 1 (E(sp1) homolog, *Drosophila*)                            ENSP00000365682                            Up                        0.018030294                                           NOT
  *NOTCH1*          Notch homolog 1                                                                               ENSP00000277541                            Up                        0.018222797                                         AD NOT
  *RYR2*            Ryanodine receptor 2 (cardiac)                                                                ENSP00000355533                            Up                        0.019085894                                           AD
  *CACYBP*          Calcyclin-binding protein                                                                     ENSP00000356652                           Down                       0.02050623                                            WNT
  *CSNK2B*          Casein kinase 2, beta polypeptide                                                             ENSP00000415615                           Down                       0.02050623                                            WNT
  *SENP2*           SUMO1/sentrin/SMT3 specific peptidase 2                                                       ENSP00000296257                            Up                        0.021603075                                           WNT
  *CHD8*            Chromodomain helicase DNA-binding protein 8                                                   ENSP00000406288                            Up                        0.021898019                                           WNT
  *DTX2*            Deltex homolog 2 (*Drosophila*)                                                               ENSP00000322885                            Up                        0.022277856                                           NOT
  *SDHC*            succinate dehydrogenase complex, subunit C, integral membrane protein, 15 kDa                 ENSP00000356953                           Down                       0.023024554                                           AD
  *LRP1*            Prolow-density lipoprotein receptor-related protein 1 Precursor (LRP)                         ENSP00000243077                            Up                        0.023159082                                           AD
  *DLL1*            Delta-like 1 (*Drosophila*)                                                                   ENSP00000355718                            Up                        0.023184387                                           NOT
  *APBB1*           Amyloid beta (A4) precursor protein binding, family B, member 1 (Fe65)                        ENSP00000299402                           Down                       0.024237411                                           AD
  *MAP3K7*          Mitogen-activated protein kinase kinase kinase 7                                              ENSP00000358335                           Down                       0.02453243                                            WNT
  *NDUFC2*          NADH dehydrogenase (ubiquinone) 1, subcomplex unknown, 2, 14.5 kDa                            ENSP00000281031                           Down                       0.025489098                                           AD
  *APLP1*           Amyloid beta (A4) precursor-like protein 1                                                    ENSP00000221891                            Up                        0.026382742                                           AD
  *BIRC2*           Baculoviral IAP repeat-containing 2                                                           ENSP00000227758                           Down                       0.026521867                                           APO
  *NDUFB5*          NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 5, 16 kDa                                  ENSP00000259037                           Down                       0.027921676                                           AD
  *PPARD*           Peroxisome proliferator-activated receptor delta                                              ENSP00000310928                            Up                        0.029747209                                           WNT
  *SKP1*            S-phase kinase-associated protein 1                                                           ENSP00000231487                           Down                       0.03098415                                            WNT
  *PRKCB*           Protein kinase C, beta                                                                        ENSP00000305355                           Down                       0.031488508                                           WNT
  *CTNNBIP1*        Catenin, beta-interacting protein 1                                                           ENSP00000366466                           Down                       0.031553064                                           WNT
  *RCAN1*           Regulator of calcineurin 1                                                                    ENSP00000320768                           Down                       0.031896183                                           AD
  *AIFM1*           Apoptosis-inducing factor, mitochondrion-associated, 1                                        ENSP00000287295                           Down                       0.031972517                                           APO
  *CALM2*           Calmodulin 2 (phosphorylase kinase, delta)                                                    ENSP00000272298                           Down                       0.032263251                                           AD
  *CAMK2D*          Calcium/calmodulin-dependent protein kinase II delta                                          ENSP00000339740                            Up                        0.034576294                                           WNT
  *SMG7*            Smg7 homolog, nonsense-mediated mRNA decay factor (*Caenorhabditis elegans*)                  ENSP00000340766                            Up                        0.034586995                                           APO
  *TBL1X*           Transducin (beta)-like 1X-linked                                                              ENSP00000217964                            Up                        0.036511455                                           WNT
  *CASP3*           Caspase 3, apoptosis-related cysteine peptidase                                               ENSP00000311032                            Up                        0.037829198                                         AD APO
  *FRAT2*           Frequently rearranged in advanced T-cell lymphomas 2                                          ENSP00000360058                            Up                        0.037835094                                           WNT
  *TCF7L2*          Transcription factor 7-like 2 (T-cell specific, HMG-box)                                      ENSP00000358404                            Up                        0.03801246                                            WNT
  *PRICKLE1*        Prickle homolog 1 (*Drosophila*)                                                              ENSP00000345064                            Up                        0.038401928                                           WNT
  *MAP3K1*          Mitogen-activated protein kinase kinase kinase 1                                              ENSP00000382423                            Up                        0.038406592                                           AD
  *MAML1*           Mastermind-like 1 (*Drosophila*)                                                              ENSP00000292599                            Up                        0.038709571                                           NOT
  *GRIN1*           Glutamate receptor, ionotropic, N-methyl D-aspartate 1                                        ENSP00000360616                            Up                        0.03916101                                            AD
  *SNCA*            Synuclein, alpha (non A4 component of amyloid precursor)                                      ENSP00000338345                           Down                       0.040205801                                           AD
  *IKBKG*           Inhibitor of kappa light polypeptide gene enhancer in B cells, kinase gamma                   ENSP00000358622                           Down                       0.04087009                                            APO
  *PRKCZ*           Protein kinase C, zeta                                                                        ENSP00000367830                           Down                       0.041055303                                           WNT
  *EP300*           MicroRNA 1281                                                                                 ENSP00000263253                            Up                        0.041373019                                         NOT WNT
  *ENDOG*           Endonuclease G                                                                                ENSP00000361725                           Down                       0.042737537                                           APO
  *PPP3CB*          Protein phosphatase 3 (formerly 2B), catalytic subunit, beta isoform                          ENSP00000378306                           Down                       0.046120071                                       AD APO WNT
  *BCL2L1*          BCL2-like 1                                                                                   ENSP00000302564                            Up                        0.046646273                                           APO
  *NDUFV2*          NADH dehydrogenase (ubiquinone) flavoprotein 2, 24 kDa                                        ENSP00000327268                           Down                       0.046908433                                           AD

Corrected *P*-values \<0.05 were considered significant. 'NOT\', 'WNT\', 'AD\', and 'APO\' represent NOTCH, WNT, Alzheimer\'s disease, and apoptosis subnetworks, respectively
